Artivion, Inc. Stock News

Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the posit

Artivion, Inc. (AORT) Q4 2023 Earnings Call Transcript

Artivion (AORT) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to earnings of $0.10 per share a year ago.

Fourth Quarter and Recent Business Highlights: Achieved revenue of $93.7 million in the fourth quarter of 2023 versus $79.4 million in the fourth quarter of 2022, an increase of 18% on a GAAP basis an

Reports of various elected U.S. officials making significant, conveniently timed trades are not, unfortunately, rare. While much focus has been given to Nancy Pelosi and her husband – and indeed, th

In May 2022, Quiver Quantitative, an alternative data platform catering to retail investors, introduced a trading bot that mimics the stock purchases made by influential US politicians.

Largely thanks to the efforts of the online investor community, interesting, suspicious, and conveniently timed trades made by elected officials in the U.S. have come under increased scrutiny in recen

Artivion, Inc. (NYSE:AORT ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group Pat Mackin - Chairman, President, and Chief Executive Offic

Artivion has used M&A to reposition itself towards growth opportunities in aortic disease care and heart valves. The company's legacy operations contribute positively to revenue and margins but have l

ATLANTA , Sept. 14, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present virtually at the up

Here is how Artivion (AORT) and Augmedix, Inc. (AUGX) have performed compared to their sector so far this year.

Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.

The average of price targets set by Wall Street analysts indicates a potential upside of 52.8% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the posit

Artivion, Inc. (NYSE:AORT ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 AM ET Company Participants Laine Morgan – Gilmartin Group Pat Mackin – Chief Executive Officer Ashley Lee – Chief